中华老年心脑血管病杂志

[1]Hill DR,Huters AD,Towne TB,et al.Parkinson's disease:advances in treatment and the syntheses of various classes of pharmaceutical drug substances[J].Chem Rev,2023,123(23):13693-13712.DOI:10.1021/acs.chemrev.3c00479.

[2]Tolosa E,Garrido A,Scholz SW,et al.Challenges in the diagnosis of Parkinson's disease[J].Lancet Neurol,2021,20(5):385-397.DOI:10.1016/S1474-4422(21)00030-2.

[3]Armstrong MJ,Okun MS.Diagnosis and treatment of Parkinson disease:a review[J].JAMA,2020,323(6):548-560.DOI:10.1001/jama.2019.22360.

[4]Morris HR,Spillantini MG,Sue CM,et al.The pathogenesis of Parkinson's disease[J].Lancet,2024,403(10423):293-304.DOI:10.1016/S0140-6736(23)01478-2.

[5]Wang J,Dai L,Chen S,et al.Protein-protein interactions regulating α-synuclein pathology[J].Trends Neurosci,2024,47(3):209-226.DOI:10.1016/j.tins.2024.01.002.

[6]BurréJ,Sharma M,Südhof TC.Cell biology and pathophysiology of α-synuclein[J].Cold Spring Harb Perspect Med,2018,8(3):a024091.DOI:10.1101/cshperspect.a024091.

[7]Hallacli E,Kayatekin C,Nazeen S,et al.The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability[J].Cell,2022,185(12):2035-20 56.DOI:10.1016/j.cell.2022.05.008.

[8]Lv YQ,Yuan L,Sun Y,et al.Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson's disease mouse model[J].Transl Neurodegener,2022,11(1):14.DOI:10.1186/s40035-022-00288-z.

[9]Yang Y,Stewart T,Zhang C,et al.Erythrocytic α-synuclein and the gut microbiome:kindling of the gut-brain axis in Parkinson's disease[J].Mov Disord,2024,39(1):40-52.DOI:10.1002/mds.2 9620.

[10]Dada ST,Hardenberg MC,Toprakcioglu Z,et al.Spontaneous nucleation and fast aggregate-dependent proliferation ofα-synuclein aggregates within liquid condensates at neutral pH[J].Proc Natl Acad Sci U S A,2023,120(9):e2208792120.DOI:10.1073/pnas.2208792120.

[11]Dai L,Wang J,Zhang X,et al.27-hydroxycholesterol drives the spread of a-synuclein pathology in Parkinson's disease[J].Mov Disord,2023,38(11):2005-2018.DOI:10.1002/mds.29577.

[12]Dai L,Wang J,Meng L,et al.The cholesterol 24-hydroxylase CYP46Al promotes α-synuclein pathology in Parkinson's disease[J].PLoS Biol,2025,23(2):e3002974.DOI:10.1371/journal.pbio.3002974.

[13]Zhou L,Guo T,Meng L,et al.N-homocysteinylation ofα-synuclein promotes its aggregation and neurotoxicity[J].Aging Cell,2023,22(3):e13745.DOIO:10.1111/acel.13745.

[14]Yuan X,Yang Y,Liu C,et al.Fine particulate matter triggersα-synuclein fibrillization and Parkinson-like neurodegeneration[J].Mov Disord,2022,37(9):1817-1830.DOI:10.1002/mds.29181.

[15]Singh Y,Trautwein C,Romani J,et al.Over expression of human alpha-synuclein leads to dysregulated microbiome/metabolites with ageing in a rat model of Parkinson disease[J].Mol Neurodegener,2023,18(1):44.DOI:10.1186/s13024-023-00628-1.

[16]Xiong J,Zhang X,Huang J,et al.Fenpropathrin,a widely used pesticide,causes dopaminergic degeneration[J].Mol Neurobiol,2016,53(2):995-1008.DOI:10.1007/s12035-014-9057-2.

[17]Zhang Z,Kang SS,Liu X,et al.Asparagine endopeptidase cleaves α-synuclein and mediates pathologic activities in Parkinson's disease[J].Nat Struct Mol Biol,2017,24(8):632-642.DOI:10.1038/nsmb.3433.

[18]L?vdal SS,Carli G,Orso B,et al.Investigating the aspect of asymmetry in brain-first versus body-first Parkinson's disease[J].NPJ Parkinsons Dis,2024,10(1):74.DOI:10.1038/s41531-024-00685-3.

[19]Yuan X,Nie S,Yang Y,et al.Propagation of pathologicα-synuclein from kidney to brain may contribute to Parkinson's disease[J].Nat Neurosci,2025,28(3):577-588.DOI:10.1038/s41593-024-01866-2.

[20]Andersen KB,Krishnamurthy A,Just MK,et al.Sympathetic and parasymp athetic subtypes of body-first Lewy body disease observed in postmortem tissue from prediagnostic individuals[J].Nat Neurosci,2025,28(5):925-936.DOI:10.1038/s41593-025-01910-9.

[21]Horsager J,Borghammer P.Brain-first vs.body-first Parkinson's disease:an update on recent evidence[J].Parkinsonism Relat Disord,2024,122:106101.DOI:10.1016/j.parkreldis.2024.106101.

[22]Tofaris GK.Initiation and progression of α-synuclein pathology in Parkinson's disease[J].Cell Life Sci,2022,79(4):210.DOI.10.1007/s00018-022-04240-2.

[23]Wu KM,Xu QH,Liu YQ,et al.Neuronal FAM171A2 mediates α-synuclein fibril uptake and drives Parkinson's disease[J].Science,2025,387(6736):892-900.DOI:10.1126/science.adp3645.

[24]Chen K,Martens YA,Meneses A,et al.LRP1 is a neuronal receptor for α-synuclein uptake and spread[J].Mol Neurodegener,2022,17(1):57.DOI:10.1186/s13024-022-00560-w.

[25]Tian Y,Meng L,Zhang Z.What is strain in neurodegenerative diseases?[J].Cell Mol Life Sci,2020,77(4):665-676.DOI:10.1007/s00018-019-03 2 98-9.

[26]Park H,Kam TI,Dawson VL,et al.α-synuclein pathology as a target in neurodegenerative diseases[J].Nat Rev Neurol,2025,21(1):32-47.DOI:10.1038/s41582-024-01043-w.

[27]Goedert M,Griesinger C,Outeiro TF,et al.Abandon the NAC in α-synuclein[J].Lancet Neurol,2024,23(7):669.DOI:10.1016/S1474-4422(24)00176-5.

[28]Han Y,Li J,Xia W,et al.Fibril fuzzy coat is important forα-synuclein pathological transmission activity[J].Neuron,2025:S0896-6273(25)00219-3.DOI:10.1016/j.neuron.2025.03.019.

[29]Magalh?es P,Lashuel HA.Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other Synucleinopathies[J].NPJ Parkinsons Dis,2022,8(1):93.DOI:10.1038/s41531-022-00357-0.

[30]Shahnawaz M,Tokuda T,Waragai M,et al.Development of a biochemical diagnosis of Parkinson disease by detection ofα-synuclein misfolded aggregates in cerebrospinal fluid[J].JAMA Neurol,2017,74(2):163-172.DOI:10.1001/jamaneurol.2016.4547.

[31]Concha-Mar am bio L,Pritzkow S,Shahnawaz M,et al.Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid[J].Nat Protoc,2023,18(4):117 9-1196.DOI:10.1038/s41596-022-00787-3.

[32]Jack CR Jr,Andrews SJ,Beach TG,et al.Revised criteria for the diagnosis and staging of Alzheimer's disease[J].Nat Med,2024,30(8):2121-2124.DOI:10.1038/s41591-024-02988-7.

[33]Smith R,Capotosti F,Schain M,et al.The α-synuclein PET tracer~(18)F ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases[J].Nat Commun,2023,14(1):6750.DOI:10.1038/s41467-023-42305-3.

[34]Xiang J,Tao Y,Xia Y,et al.Development of an α-synuclein positron emission tomography tracer for imaging synucleinopathies[J].Cell,2023,186(16):3350-3367.DOI:10.1016/j.cell.2023.06.004.

[35]Kuebler L,Buss S,Leonov A,et al.~(11)CMODAG-001-towards a PET tracer targeting α-synuclein aggregates[J].Eur J Nucl Med Mol Imaging,2021,48(6):1759-1772.DOI:10.1007/s00259-020-05133-x.

[36]Pees A,Tong J,Birudaraju S,et al.Development of pyridothiophene comp ounds for PET imaging of α-synuclein[J].Chemistry,2024,30(23):e202303921.DOI:10.1002/chem.202303921.

[37]Endo H,Ono M,Takado Y,et al.Imaging α-synuclein pathologies in animal models and patients with Parkinson's and related diseases[J].Neuron,2024,112(15):2540-2557.DOI:10.1016/j.neuron.2024.05.006.

[38]H?glinger GU,Adler CH,Berg D,et al.A biological classification of Parkinson's disease:the SynNeurGe research diagnostic criteria[J].Lancet Neurol,2024,23(2):191-204.DOI:10.1016/S1474-4422(23)00404-0.

[39]Simuni T,Chahine LM,Poston K,et al.A biological definition of neuronal α-synuclein disease:towards an integrated staging system for research[J].Lancet Neurol,2024,23(2):178-190.DOI:10.1016/S1474-4422(23)00405-2.

[40]Alfaidi M,Barker RA,Kuan WL.An update on immune-based alpha-synuclein trials in Parkinson's disease[J].J Neurol,2024,272(1):21.DOI:10.1007/s00415-024-12770-x.

[41]Zampar S,Di Gregorio SE,Grimmer G,et al."Prion-like"seeding and propagation of oligomeric protein assemblies in neurodegen erative disorders[J].Front Neurosci,2024,18:1436262.DOI:10.3389/fnins.2024.1436262.

[42]Fang C,Hernandez P,Liow K,et al.Buntanetap,a novel translational inhibitor of multiple neurotoxic proteins,proves to be safe and promising in both Alzheimer's and Parkinson's patients[J].J Prev Alzheimers Dis,2023,10(1):25-33.DOI:10.14283/jpad.2022.8 4.

[43]Etel?inen TS,Kilpel?inen TP,Ignatius A,et al.Removal of proteinase K resistant aSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model[J].Neuropharmacology,2022,218:109213.DOI:10.1016/j.neuropharm.2022.109213.